Kasri, Amal
Camporesi, Elena
Gkanatsiou, Eleni
Boluda, Susana
Brinkmalm, Gunnar
Stimmer, Lev
Ge, Junyue
Hanrieder, Jörg
Villain, Nicolas
Duyckaerts, Charles
Vermeiren, Yannick
Pape, Sarah E.
Nicolas, Gaël
Laquerrière, Annie
De Deyn, Peter Paul
Wallon, David
Blennow, Kaj
Strydom, Andre
Zetterberg, Henrik
Potier, Marie-Claude http://orcid.org/0000-0003-2462-7150
Funding for this research was provided by:
Agence Nationale de la Recherche (COEN4024, JPND ANR-17-JPCD-003, ANR-10-AIHU-06)
Article History
Received: 2 February 2024
Revised: 11 June 2024
Accepted: 11 June 2024
First Online: 18 July 2024
Declarations
:
: KB has served as a consultant and at advisory boards for Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). AS has served on scientific advisory boards for AC-Immune, and ProMIS Neurosciences.